This document discusses treatment issues for desmoplastic ganglioglioma and mentions etoposide and vincristine as potential treatments. It provides a median follow up time of 12 years with a range of 9 months to 35 years for one group, and a median follow up time of 3.5 years with a range of 1.4 to 11.7 years for another group.